967 results on '"Björkholm, M."'
Search Results
2. Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells
3. MSR132 Integrating Relative Survival Framework for Survival Extrapolation in Multi-State Models—An Application to Predicting Quality-Adjusted Life Years for Chronic Myeloid Leukemia Patients
4. Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia
5. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
6. Fludarabine for the Treatment of Advanced Chronic Lymphocytic Leukemia: Results of a Prospective Randomized Comparison with Cyclophosphamide, Doxorubicin and Prednisone
7. Mitoxantrone, Etoposide and Cytarabine in the Treatment of Acute Myelocytic Leukemia (AML)
8. Genomic analysis of the clonal origin and evolution of acute promyelocytic leukemia in a unique patient with a very late (17 years) relapse
9. Brain tumors in patients with myotonic dystrophy: a population-based study
10. Telomerase reverse transcriptase promotes epithelial–mesenchymal transition and stem cell-like traits in cancer cells
11. Long-term treatment of invasive sinus, tracheobroncheal, pulmonary and intracerebral aspergillosis in acute lymphoblastic leukaemia
12. Dendritic Cells in Bone Marrow at Diagnosis and after Chemotherapy in Adult Patients with Acute Myeloid Leukaemia
13. Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma
14. HIGH RISK AGGRESSIVE B‐CELL LYMPHOMA ON THE LIQUID BIOPSY
15. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
16. Validation of an Extended Version of the SEIQoL-DW in a Cohort of Hodgkin Lymphoma’ Survivors
17. Autologous and allogeneic stem cell transplantation in adult ALL: the Swedish Adult ALL Group experience
18. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping
19. Determinants of Health-Related Quality of Life in Long-Term Survivors of Hodgkin's Lymphoma
20. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease
21. Individual quality of life in long-term survivors of Hodgkin's lymphoma – a comparative study
22. Negligible clinical effects of thalidomide in patients with myelofibrosis with myeloid metaplasia
23. A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients
24. Oral etoposide in patients with hematological malignancies: A clinical and pharmacokinetic study
25. Flow cytometry and allele-specific oligonucleotide PCR are equally effective in detection of minimal residual disease in ALL
26. Routine bone scintigraphy is of limited value in the clinical assessment of untreated patients with Hodgkin's disease
27. Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study
28. Arterial blood oxygenation, maximum exercise capacity and oxygen transport in patients before and after autologous peripheral blood progenitor cell transplantation
29. Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation – a prospective study
30. Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteremia, clinical findings and serum cytokine pattern
31. Sequential multidrug chemotherapy (CHOP-VA-MB) in patients with high-grade non-Hodgkin’s lymphoma—a 20-year follow-up
32. Quality of life before and one year following stem cell transplantation using an individualized and a standardized instrument
33. Suicide in multiple myeloma and acute myeloid leukaemia
34. Do steroids increase lymphoma risk? A case–control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis
35. Risk of haematopoietic cancer in patients with inflammatory bowel disease
36. Risk profile and outcome in Hodgkinʼs lymphoma: is obesity beneficial?
37. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkinʼs lymphoma
38. Granulocyte-macrophage colony-stimulating factor to increase efficacy of mitoxantrone, etoposide and cytarabine in previously untreated elderly patients with acute myeloid leukaemia: a Swedish multicentre randomized trial
39. Long-term follow-up of patients ≥60 yr old with acute myeloid leukaemia treated with intensive chemotherapy: A randomised trial of aclarubicin vs. daunorubicin in combination with cytosine arabinoside and thioguanine
40. Early response to chemotherapy: a surrogate for final outcome of Hodgkin's disease patients that should influence initial treatment length and intensity?
41. Patterns of clinical presentation, treatment, and outcome in patients with Waldenstrom's macroglobulinemia: A two-institution study
42. Biological markers may add to prediction of outcome achieved by the international prognostic score in Hodgkin's disease
43. The measurement of venous haematocrit in patients with polycythaemia vera
44. Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population‐based study in Sweden
45. PS1463 SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION-BASED COHORT STUDY IN SWEDEN AND NORWAY
46. PF641 CHARACTERIZATION OF TREATMENTS AND REAL-LIFE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION IN SWEDEN
47. YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA INCLUDING BCL-2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE-DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS
48. Severe aplastic anemia associated with seronegative community-acquired hepatitis C virus infection
49. Clonal blood B-cell excess in relation to prognosis in untreated non-leukemic patients With non-Hodgkin’s lymphoma (NHL)
50. DOSE-DENSE CHEMOIMMUNOTHERAPY AND CNS PROPHYLAXIS IN PATIENTS WITH HIGH-RISK DLBCL: A COMPARISON OF NORDIC CRY-04 AND CHIC STUDIES
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.